Literature DB >> 12354357

Prevention of liver cancer.

Kathryn Z Guyton1, Thomas W Kensler.   

Abstract

Hepatocellular carcinoma (HCC) is among the most prevalent and deadly cancers worldwide. Prominent risk factors for HCC include viral hepatitis infection; dietary exposure to hepatotoxic contaminants such as aflatoxins; alcoholism; smoking; and male gender. This review highlights ongoing efforts in HCC prevention. Strategies include vaccination against, and treatment of, viral hepatitis infection. In addition to interferon alpha, an acyclic retinoid (all-trans-3,7,11, 15-tetramethyl-2,4,6,10,14-hexadecapentanoic acid), glycyrrhizin and ginseng are currently under clinical investigation for HCC prevention in Japanese hepatitis C patients. Several recent clinical studies in a Chinese region of pervasive aflatoxin contamination also support the approach of favorably altering aflatoxin metabolism and excretion using the chemopreventive agents oltipraz or chlorophyllin. Agents exhibiting chemopreventive efficacy in preclinical HCC models include vitamins A, D, and E, herbal extracts, a 5alpha-reductase inhibitor, green tea, and D-limonene. Efforts to elucidate the molecular lesions and processes underlying HCC development have identified several putative molecular targets for preventive interventions. These include genes and gene products controlling viral replication, carcinogen metabolism, signal transduction, cell-cycle arrest, apoptosis, proliferation, and oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12354357     DOI: 10.1007/s11912-002-0057-4

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  68 in total

1.  Lack of p53 accelerates hepatocarcinogenesis in transgenic mice constitutively overexpressing c-myc in the liver.

Authors:  R Klocke; T Bartels; G Jennings; K Brand; R Halter; M Strauss; D Paul
Journal:  FASEB J       Date:  2001-06       Impact factor: 5.191

2.  Inhibition of N-nitrosodiethylamine-induced hepatocarcinogenesis by Picroliv.

Authors:  N V Rajeshkumar; R Kuttan
Journal:  J Exp Clin Cancer Res       Date:  2000-12

3.  Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan.

Authors:  C A Sun; L Y Wang; C J Chen; S N Lu; S L You; L W Wang; Q Wang; D M Wu; R M Santella
Journal:  Carcinogenesis       Date:  2001-08       Impact factor: 4.944

4.  Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer.

Authors:  P A Egner; J B Wang; Y R Zhu; B C Zhang; Y Wu; Q N Zhang; G S Qian; S Y Kuang; S J Gange; L P Jacobson; K J Helzlsouer; G S Bailey; J D Groopman; T W Kensler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

5.  Vertical transmission of hepatitis B virus despite maternal lamivudine therapy.

Authors:  Syed N Kazim; Salma M Wakil; Luqman A Khan; Seyed E Hasnain; Shiv K Sarin
Journal:  Lancet       Date:  2002-04-27       Impact factor: 79.321

6.  The little mutation suppresses DEN-induced hepatocarcinogenesis in mice and abrogates genetic and hormonal modulation of susceptibility.

Authors:  J M Bugni; T M Poole; N R Drinkwater
Journal:  Carcinogenesis       Date:  2001-11       Impact factor: 4.944

7.  Inhibition of ebselen on aflatoxin B(1)-induced hepatocarcinogenesis in Fischer 344 rats.

Authors:  C F Yang; J Liu; S Wasser; H M Shen; C E Tan; C N Ong
Journal:  Carcinogenesis       Date:  2000-12       Impact factor: 4.944

8.  Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C.

Authors:  H Toyoda; T Kumada; S Nakano; I Takeda; K Sugiyama; S Kiriyama; Y Sone; M Tanikawa; Y Hisanaga; K Hayashi; T Honda
Journal:  Oncology       Date:  2001       Impact factor: 2.935

Review 9.  Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives.

Authors:  M Okuno; S Kojima; H Moriwaki
Journal:  J Gastroenterol Hepatol       Date:  2001-12       Impact factor: 4.029

10.  Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus.

Authors:  H Kaneto; S Sasaki; H Yamamoto; F Itoh; M Toyota; H Suzuki; I Ozeki; N Iwata; T Ohmura; T Satoh; Y Karino; T Satoh; J Toyota; M Satoh; T Endo; M Omata; K Imai
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

View more
  14 in total

1.  Cancer chemoprevention by dietary chlorophylls: a 12,000-animal dose-dose matrix biomarker and tumor study.

Authors:  Tammie J McQuistan; Michael T Simonich; M Margaret Pratt; Cliff B Pereira; Jerry D Hendricks; Roderick H Dashwood; David E Williams; George S Bailey
Journal:  Food Chem Toxicol       Date:  2011-11-03       Impact factor: 6.023

Review 2.  Therapeutic properties of green tea against environmental insults.

Authors:  Lixia Chen; Huanbiao Mo; Ling Zhao; Weimin Gao; Shu Wang; Meghan M Cromie; Chuanwen Lu; Jia-Sheng Wang; Chwan-Li Shen
Journal:  J Nutr Biochem       Date:  2016-05-27       Impact factor: 6.048

3.  Physical properties of gum karaya-starch-essential oil patches.

Authors:  Yulia Shcherbina; Zvi Roth; Amos Nussinovitch
Journal:  AAPS PharmSciTech       Date:  2010-08-14       Impact factor: 3.246

Review 4.  Anisi Stellati Fructus, a Significant Traditional Chinese Medicine (TCM) Herb and Its Bioactivity against Gastric Cancer.

Authors:  Maryam Khan; Saba Shamim
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-09       Impact factor: 2.650

5.  Hydrogen peroxide is a second messenger in phase 2 enzyme induction by cancer chemopreventive dithiolethiones.

Authors:  Ryan Holland; Mettachit Navamal; Murugesan Velayutham; Jay L Zweier; Thomas W Kensler; James C Fishbein
Journal:  Chem Res Toxicol       Date:  2009-08       Impact factor: 3.739

6.  Inhibition of growth and metastasis of human gastric cancer implanted in nude mice by d-limonene.

Authors:  Xiao-Guang Lu; Li-Bin Zhan; Bing-An Feng; Ming-Yang Qu; Li-Hua Yu; Ji-Hong Xie
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

7.  Bioinformatic screening of human ESTs for differentially expressed genes in normal and tumor tissues.

Authors:  Abdel Aouacheria; Vincent Navratil; Audrey Barthelaix; Dominique Mouchiroud; Christian Gautier
Journal:  BMC Genomics       Date:  2006-04-26       Impact factor: 3.969

8.  Chemopreventive effect of selenium and Chinese medicinal herbs on N-nitrosobis(2-oxopropyl)amine-induced hepatocellular carcinoma in Syrian hamsters.

Authors:  Chang-Yin Lee; Yi-Chao Hsu; Jir-You Wang; Chien-Chih Chen; Jen-Hwey Chiu
Journal:  Liver Int       Date:  2008-07       Impact factor: 5.828

9.  Differential mechanism of Escherichia coli Inactivation by (+)-limonene as a function of cell physiological state and drug's concentration.

Authors:  Beatriz Chueca; Rafael Pagán; Diego García-Gonzalo
Journal:  PLoS One       Date:  2014-04-04       Impact factor: 3.240

10.  A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer.

Authors:  Hephzibah Rani S Tagaram; Dhimant Desai; Guangfu Li; Dai Liu; C Bart Rountree; Kavitha Gowda; Arthur Berg; Shantu Amin; Kevin F Staveley-O'Carroll; Eric T Kimchi
Journal:  Pharmaceuticals (Basel)       Date:  2016-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.